株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

パーキンソン病におけるバイオマーカー

Biomarkers in Parkinson's Disease

発行 Insight Pharma Reports 商品コード 309637
出版日 ページ情報 英文 81 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.81円で換算しております。
Back to Top
パーキンソン病におけるバイオマーカー Biomarkers in Parkinson's Disease
出版日: 2014年08月01日 ページ情報: 英文 81 Pages
概要

当レポートでは、パーキンソン病の特定および診断に用いられるバイオマーカーについて調査し、バイオマーカーの概要、神経変性疾患全般におけるバイオマーカーの動向、パーキンソン病を特定する既存の遺伝子マーカーとバイオマーカー候補の概要、バイオマーカー研究に関する専門家へのインタビュー、治験およびパイプラインの動向などをまとめています。

エグゼクティブサマリー

第1章 本書の焦点

第2章 バイオマーカーとその臨床的有用性

  • バイオマーカーとは
  • バイオマーカーの長所
  • 臨床的エンドポイントとサロゲートエンドポイント
  • サロゲートエンドポイントとしてのバイオマーカーの長所
  • サロゲートエンドポイントとしてのバイオマーカーの短所
  • バイオマーカーの有効性の確認

第3章 神経変性疾患におけるバイオマーカー

第4章 パーキンソン病

  • パーキンソン病とは
  • パーキンソン病に関係する遺伝因子
    • PARK2 (パーキン/ユビキチンE3リガーゼ)
    • PINK1 (PTEN誘導キナーゼ1タンパク質)
    • GBA (グルコセレブロシダーゼ)
  • パーキンソン病で有望視されているバイオマーカー
    • SNCA (α-シヌクレイン)
    • PARK7 (DJ-1タンパク質)
    • LRRK2 (ダーダリンタンパク質)
    • その他
  • Andrew West博士へのインタビュー
    • 研究の背景
    • LRRK2プロテインキナーゼ
    • パーキンソン病の研究
    • メリット
    • 課題と制約
    • パーキンソン病の展望

第5章 Penn State Hershey Medical Center

  • 背景
  • パーキンソン氏病診断のMRI
  • Xuemei Huang博士へのインタビュー
    • 研究の背景
    • 非侵襲的イメージングツール
    • メリット
    • 課題と制約
    • パーキンソン病の展望

Atlantic Biomarkers

  • 背景
  • バイオマーカーのための質量分析アッセイ
  • 医療への影響
  • Andreas Jeromin博士へのインタビュー
    • 企業背景
    • ニューロバイオマーカーの研究
    • 質量分析ベースのアッセイ

第6章 調査結果

第7章 パーキンソン病の治験およびパイプラインの情報

参考

Cambridge Healthcare Instituteについて

図表

目次

Biomarkers in Parkinson's Disease is focused on the biomarker identification and development in patients with Parkinson's Disease. As a spin-off of Biomarkers: Discovery and Development for a Diagnostic Approach to Neurodegenerative Disorders, this report focuses on the Parkinson's Disease space featured in the parent report, highlighting several biomarker targets under investigation and the progress that has been made in the industry. With regards to employing the use of biomarkers for Parkinson's Disease, Biomarkers in Parkinson's Disease captures market growth of biomarkers, advantages, disadvantages, and validation techniques.

Experts interviewed in this report include:

  • Dr. Andrew West, Associate Professor of Neurology and Neurobiology and Co-Director, Center for Neurodegeneration and Experimental Therapeutics
  • Dr. Xuemei Huang, Professor and Vice Chair, Department of Neurology; Professor of Neurosurgery, Radiology, Pharmacology, and Kinesiology Director; Hershey Brain Analysis Research Laboratory for Neurodegenerative Disorders, Penn State University-Milton, S. Hershey Medical Center Department of Neurology
  • Dr. Andreas Jeromin, CSO and President of Atlantic Biomarkers

Also available in this report is extensive survey data exclusively conducted for this report. Illustrated by 30 figures captured in an in-depth analysis, this section features insight into targets under investigation, challenges, advantages, and desired features of future diagnostic applications.

To add even more to the robustness of this report, Insight Pharma Reports also engineered a table of clinical trial information and pipeline data from multiple databases related to Parkinson's Disease. This table features companies, targets, clinical phases, and brief target/product descriptions.

Executive Summary

Biomarkers have been a heavily studied topic of interest, and recently on the rise is the interest in neurodegenerative disorders, particularly Parkinson's Disease. Although there are many techniques used to track Parkinson's Disease progression, this report will primarily focus on blood-based and cerebrospinal fluid-based biomarkers currently under investigation. In addition to covering extensive background information, this report will also highlight market growth and outlook, and feature clinical trial and pipeline information.

After the introduction, Chapters 2 and 3 highlight background information on neurodegenerative disorders and include definitions and elaborate examples of different types of biomarkers used in the clinic. Chapter 2 concludes with market growth, advantages of biomarkers, disadvantages of biomarkers, and validation techniques. Chapters 3 gives a brief overview of neurodegenerative disorders, also speaking to the market growth and rise in interest in biomarkers over the years.

Chapter 4 gives specifics on Parkinson's Disease, featuring definitions, symptoms, genetic markers, and current research. As the second leading cause of neurodegeneration in the aging population, researchers are scrambling to find biomarkers that will provide enough information for therapeutic action. Featured in this chapter is an interview with Dr. Andrew West, who speaks about his research and successes with the gene LRRK2. This chapter also provides an extensive amount of detail speaking to genetic targets and their use as biomarkers. Furthermore, Chapter 5 features Dr. Xuemei Huang (Professor and Vice Chair, Department of Neurology; Professor of Neurosurgery, Radiology, Pharmacology, and Kinesiology Director; Hershey Brain Analysis Research Laboratory for Neurodegenerative Disorders, Penn State University-Milton, S. Hershey Medical Center Department of Neurology) and Dr. Andreas Jeromin, CSO and President of Atlantic Biomarkers. These chapters provide insight to utilizing biomarkers as a diagnostic for Parkinson's Disease.

Chapter 6 includes an elaborate survey analysis exclusively done for this report. Qualifying participants worked with neurobiomarkers, neurodiagnostics, or both. With over 30 survey figures depicting the general R&D group working in this space, this section provides information including: research demographics, targets under investigation, challenges, advantages, and desired features of future diagnostic applications.

Finally, Insight Pharma Reports also created a table of clinical and pipeline information related to Parkinson's Disease.

Executive Summary

Biomarkers have been a heavily studied topic of interest, and recently on the rise is the interest in neurodegenerative disorders, particularly Parkinson's Disease. Although there are many techniques used to track Parkinson's Disease progression, this report will primarily focus on blood-based and cerebrospinal fluid-based biomarkers currently under investigation. In addition to covering extensive background information, this report will also highlight market growth and outlook, and feature clinical trial and pipeline information.

After the introduction, Chapters 2 and 3 highlight background information on neurodegenerative disorders and include definitions and elaborate examples of different types of biomarkers used in the clinic. Chapter 2 concludes with market growth, advantages of biomarkers, disadvantages of biomarkers, and validation techniques. Chapters 3 gives a brief overview of neurodegenerative disorders, also speaking to the market growth and rise in interest in biomarkers over the years.

Chapter 4 gives specifics on Parkinson's Disease, featuring definitions, symptoms, genetic markers, and current research. As the second leading cause of neurodegeneration in the aging population, researchers are scrambling to find biomarkers that will provide enough information for therapeutic action. Featured in this chapter is an interview with Dr. Andrew West, who speaks about his research and successes with the gene LRRK2. This chapter also provides an extensive amount of detail speaking to genetic targets and their use as biomarkers. Furthermore, Chapter 5 features Dr. Xuemei Huang (Professor and Vice Chair, Department of Neurology; Professor of Neurosurgery, Radiology, Pharmacology, and Kinesiology Director; Hershey Brain Analysis Research Laboratory for Neurodegenerative Disorders, Penn State University-Milton, S. Hershey Medical Center Department of Neurology) and Dr. Andreas Jeromin, CSO and President of Atlantic Biomarkers. These chapters provide insight to utilizing biomarkers as a diagnostic for Parkinson's Disease.

Chapter 6 includes an elaborate survey analysis exclusively done for this report. Qualifying participants worked with neurobiomarkers, neurodiagnostics, or both. With over 30 survey figures depicting the general R&D group working in this space, this section provides information including: research demographics, targets under investigation, challenges, advantages, and desired features of future diagnostic applications.

Finally, Insight Pharma Reports also created a table of clinical and pipeline information related to Parkinson's Disease.

Table of Contents

Executive Summary

CHAPTER 1: The Focus of this Report

CHAPTER 2: Biomarkers and Their Clinical Utility

  • What are Biomarkers?
  • Advantages of Biomarkers
  • Clinical Endpoints vs. Surrogate Endpoints
  • Advantages of Biomarkers as Surrogate Endpoints
  • Disadvantages to Biomarkers as Surrogate Endpoints
  • How are Biomarkers Validated?

CHAPTER 3: Biomarkers in Neurodegenerative Disorders

CHAPTER 4: Parkinson's Disease

  • What is Parkinson's Disease?
  • Genetic Factors Linked to Parkinson's Disease
    • PARK2 (parkin/ubiquitin E3 ligase)
    • PINK1 (PTEN-induced kinase 1 protein)
    • GBA (glucocerebrosidase)
  • Promising Biomarkers for Parkinson's Disease
    • SNCA (α-synuclein)
    • PARK7 (DJ-1 protein)
    • LRRK2 (dardarin protein)
    • Other biomarkers
  • Interview with Dr. Andrew West
    • Research Background
    • LRRK2 Protein Kinase
    • Advantages
    • Challenges and Limitations
    • Parkinson's Disease Outlook

CHAPTER 5: Penn State Hershey Medical Center

  • Research Background
  • MRI for Parkinson's Disease Diagnosis
  • Interview with Dr. Xuemei Huang
    • Research Background
    • Non-Invasive Imaging Tool
    • Advantages
    • Challenges and Limitations
    • Parkinson's Disease Outlook

Atlantic Biomarkers

  • Research Background
  • Mass-Spectrometry Assays for Biomarkers
  • Impact on Healthcare
  • Interview with Dr. Andreas Jeromin
    • Company Background
    • Neurobiomarker Research
    • Mass Spectrometry-Based Assays

CHAPTER 6: Survey Results

CHAPTER 7: Clinical Trials and Pipeline Information in Parkinson's Disease

References

About Cambridge Healthtech Institute

FIGURES

  • Figure 2.1: Growth of Interest in Biomarkers
  • Figure 2.2: Biomarker Presence in Diagnostic Development vs. Therapeutic Development
  • Figure 3.1: Comparison of Disease Categories
  • Figure 3.2: Growth of Interest in Biomarkers for Neurology
  • Figure 3.3: Growth of Interest in Biomarkers for Parkinson's Disease
  • Figure 6.1: How Would You Categorize Your Organization?
  • Figure 6.2: Which Neurodegenerative Condition are You Currently Studying?
  • Figure 6.3: Which Targets for Huntington's Disease (HD) are You Currently Studying?
  • Figure 6.4: What is the Clinical Status of Your Target(s) for HD?
  • Figure 6.5: When Do You Expect Your Targets for HD to Enter Clinical Trials?
  • Figure 6.6: When Do You Expect Your Target to be an Available Therapeutic for HD?
  • Figure 6.7: Which Targets for Amyotrophic Lateral Sclerosis (ALS) are You Currently Studying?
  • Figure 6.8: What is the Clinical Status of Your Target(s) for ALS?
  • Figure 6.9: When Do You Expect Your Targets for ALS to Enter Into Clinical Trials?
  • Figure 6.10: When Do You Expect Your Target to be an Available Therapeutic for ALS?
  • Figure 6.11: Which Targets for Multiple Sclerosis (MS) are You Currently Studying?
  • Figure 6.12: What is the Clinical Status of Your Target(s) for MS?
  • Figure 6.13: When Do You Expect Your Targets for MS to Enter Into Clinical Trials?
  • Figure 6.14: When Do You Expect Your Target for MS to be an Available Therapeutic?
  • Figure 6.15: Which Signatures for Alzheimer's Disease (AD) are You Currently Studying?
  • Figure 6.16: What is the Clinical Status of Your Target(s) for AD?
  • Figure 6.17: When Do You Expect Your Targets for AD to Enter Into Clinical Trials?
  • Figure 6.18: When Do You Expect Your Target to be an Available Therapeutic for AD?
  • Figure 6.19: Which Signatures for Parkinson's Disease (PD) are You Currently Studying?
  • Figure 6.20: What is the Clinical Status of Your Target(s) for PD?
  • Figure 6.21: When Do You Expect Your Targets for PD to Enter Into Clinical Trials?
  • Figure 6.22: When Do You Expect Your Targets for PD to be an Available Therapeutic?
  • Figure 6.23: How Would You Describe Your Line of Research?
  • Figure 6.24: With Respect to Neurodiagnostics, Which Diagnostic Tools are You Developing for Biomarker Signatures?
  • Figure 6.25: With Respect to Neurodiagnostics, What are Challenges You Have Encountered with Your Diagnostic Development?
  • Figure 6.26: With Respect to Biomarker Development, What Tools are You Using to Identify Biomarker Signatures?
  • Figure 6.27: With Respect to Biomarker Development, What are Challenges You Have Encountered with Your Therapeutic Discovery/Development?
  • Figure 6.28: With Respect to Biomarker Therapeutics, What Tools are You Using to Identify Biomarker Signatures?
  • Figure 6.29: With Respect to Biomarker Therapeutics, What are Challenges You Have Encountered with Your Therapeutic Discovery/Development?
  • Figure 6.30: Which Imaging Techniques do You Feel are the Most Beneficial for Studying the Effects of Neurodegenerative Diseases?
  • Figure 6.31: Which Therapeutics do You Feel will be the Most Beneficial for Neurodegenerative Diseases?

TABLE

  • Table 2.1: Clinical Applications of Biomarkers as Surrogate Endpoints
Back to Top